Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03916627
Title Neoadjuvant Cemiplimab for the Treatment of Resectable NSCLC, HCC, and HNSCC
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Regeneron Pharmaceuticals
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA

Facility Status City State Zip Country Details
Icahn School of Medicine at Mount Sinai RECRUITING New York New York 10029 United States Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field